BriaCell Therapeutics (TSE:BCT) Posts Quarterly Earnings Results, Beats Expectations By $0.60 EPS

BriaCell Therapeutics (TSE:BCT) issued its quarterly earnings results on Monday. The company reported C($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.70) by C$0.60, reports.

BriaCell Therapeutics Trading Down 13.6 %

Shares of BCT stock opened at C$1.02 on Thursday. The stock has a market cap of C$36.56 million, a P/E ratio of -2.30 and a beta of 1.83. The stock has a 50 day simple moving average of C$1.08 and a 200 day simple moving average of C$1.58. BriaCell Therapeutics has a 1 year low of C$0.64 and a 1 year high of C$8.00.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.